Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer - Episode 3
CDK4/6 Inhibitors Treatment Options in the eBC Setting
Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2– early-stage breast cancer (eBC) guide clinical decision-making, exploring real-world adherence to these guidelines, the complexity of risk stratification in various clinical scenarios, and the role of clinical factors, biomarkers, and advanced testing methodologies (including RSClin N+, next-generation sequencing [NGS], fluorescence in situ hybridization [FISH], immunohistochemistry [IHC], and circulating DNA [ctDNA]) in defining “high-risk” patients and guiding treatment strategies.
Video Player is loading.
Video content above is prompted by the following:
- Please briefly describe the predominant role of CDK4/6 inhibitors in HR+/HER2– early breast cancer treatment.
- Given your experience and the positive trials in the metastatic setting, how comfortable are you with using CDK4/6 inhibitors in eBC?
- Can you provide an overview of the current landscape of treatment options for HR+/HER2– eBC?
- What are the limitations of current treatments?
- How are newer strategies like adjuvant CDK4/6 and PARP inhibitors changing the paradigm?
- What is the rationale for combining CDK4/6 inhibitors with endocrine therapy in early-stage HR+/HER2– breast cancer?
Related Content:
